Mizuho reiterates Apellis stock rating citing M&A process details By Investing.com

Biogen’s $41 per share all-cash acquisition of Apellis values the company at about $5.6 billion, an 86% premium to the 90-day VWAP, and Mizuho said the deal is an outstanding outcome for Apellis shareholders. The firm reiterated a Neutral rating on Apellis and maintained an Outperform on Biogen with a $236 target. While multiple analysts shifted to Neutral/Market Perform after the announcement, the transaction appears on track to close.

Analysis

This is less a fundamental re-rate than a clean event-driven resolution: the main edge now shifts from valuation debate to closing mechanics. The fact that multiple outreach rounds failed to surface a topping bid suggests the spread is likely to compress on any confirmation of regulatory/financing progress, while the remaining economics are increasingly about the CVR and its probability-weighted value rather than headline cash. That structure also makes the downside asymmetric for anyone still long APLS on a standalone story—once the deal is viewed as “best available,” residual fundamental optionality is effectively transferred to BIIB.

The second-order winner is BIIB, but not in the obvious “deal accretion” sense alone. Biogen is effectively buying an under-optimized launch/franchise asset with a negotiated floor on consideration, which can be attractive if management believes it can harvest commercial synergies or improve execution where the target could not. The more important market signal is that the sector’s M&A bar may be lower than expected for differentiated neurology assets with at least one commercial pillar, which could re-open optionality across mid-cap biotech names that are strategically valuable but cash-flow challenged.

The key risk is not strategic value; it is timeline slippage or a CVR haircut if Syfovre revenue underwhelms, which would primarily matter for arbitrage funds and holders underwriting the tail. On a 1-6 month horizon, the trade is about certainty versus dispersion: once spreads are tight, incremental upside in APLS is capped, while BIIB still carries execution risk if investors overpay for the asset versus a weak integration backdrop. Consensus appears to be underappreciating how much of APLS’s post-announcement float will become mechanically de-risked and how that can create temporary pressure in the name until close.

Key Decisions for Investors

• Long BIIB vs short XBI for 1-3 months: express the view that a disciplined, asset-specific acquisition should be viewed more favorably than the broader biotech basket; target modest relative outperformance if closing confidence improves.
• Avoid standalone long APLS after the announcement unless trading the spread: the remaining upside is largely the CVR and deal certainty, so risk/reward is poor once the market has priced the headline cash value.
• For event-driven books, consider a small long APLS / short BIIB merger-arb hedge only if the implied spread widens on any regulatory delay; otherwise the carry is unattractive versus the limited residual upside.
• Use BIIB pullbacks to build a tactical long over 2-6 weeks if the market overfocuses on purchase-price optics; the downside from deal concerns should be less than the upside from removing uncertainty around a strategic asset.